We are live on ! Find out more
VIA

Virtus Investment Advisers Portfolio holdings

AUM $363M
1-Year Est. Return 34.89%
This Fund
S&P 500
This Quarter Est. Return
+9.85%
1 Year Est. Return
+34.89%
3 Year Est. Return
+131.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$349M
AUM Growth
+$53.4M
Cap. Flow
+$36.4M
Cap. Flow %
10.41%
Top 10 Hldgs %
7.12%
Holding
478
New
39
Increased
273
Reduced
76
Closed
38

Top Buys

Rank Stock Value
1
OXLC
Oxford Lane Capital
OXLC
+$2.36M
2
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$1.99M
3
LRCX icon
Lam Research
LRCX
+$1.97M
4
IDXX icon
Idexx Laboratories
IDXX
+$1.96M
5
TKO icon
TKO Group
TKO
+$1.96M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$1.85M
2
KKR icon
KKR & Co
KKR
+$1.62M
3
UAL icon
United Airlines
UAL
+$1.62M
4
CBRE icon
CBRE Group
CBRE
+$1.61M
5
NU icon
Nu Holdings
NU
+$1.58M

Sector Composition

Rank Sector Weight
1 Financials 33.25%
2 Healthcare 17.27%
3 Technology 14.61%
4 Industrials 8.9%
5 Consumer Discretionary 5.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZYME icon
376
Zymeworks
ZYME
$1.71B
$148K 0.04%
8,686
+1,508
+21% +$21.6K
ATXS
377
DELISTED
Astria Therapeutics
ATXS
$148K 0.04%
20,319
+3,527
+21% +$23.9K
CRNX icon
378
Crinetics Pharmaceuticals
CRNX
$8.93B
$147K 0.04%
3,537
+614
+21% +$19.6K
VERA icon
379
Vera Therapeutics
VERA
$2.27B
$147K 0.04%
5,052
+876
+21% +$20.3K
CLDX icon
380
Celldex Therapeutics
CLDX
$3.37B
$145K 0.04%
5,592
+971
+21% +$22.5K
ABUS icon
381
Arbutus Biopharma
ABUS
$907M
$144K 0.04%
31,784
+5,518
+21% +$20.3K
CMPS
382
Compass Pathways
CMPS
$1.78B
$144K 0.04%
25,174
+4,370
+21% +$19.6K
GPCR icon
383
Structure Therapeutics
GPCR
$3.82B
$143K 0.04%
5,121
+889
+21% +$17.7K
IRON icon
384
Disc Medicine
IRON
$3.01B
$143K 0.04%
2,158
+374
+21% +$22.2K
XNCR icon
385
Xencor
XNCR
$1.6B
$142K 0.04%
12,066
+2,094
+21% +$18.2K
ORIC icon
386
Oric Pharmaceuticals
ORIC
$1.41B
$141K 0.04%
11,767
+2,043
+21% +$21.5K
ACLX
387
DELISTED
Arcellx
ACLX
$140K 0.04%
1,711
+297
+21% +$21.4K
TSHA icon
388
Taysha Gene Therapies
TSHA
$1.83B
$140K 0.04%
42,938
+7,454
+21% +$21.1K
XENE icon
389
Xenon Pharmaceuticals
XENE
$6.21B
$139K 0.04%
3,469
+602
+21% +$21.2K
IDYA icon
390
IDEAYA Biosciences
IDYA
$3.54B
$139K 0.04%
5,107
+887
+21% +$21.5K
KYMR icon
391
Kymera Therapeutics
KYMR
$9.03B
$136K 0.04%
2,406
+418
+21% +$18.9K
IMNM icon
392
Immunome
IMNM
$2.91B
$136K 0.04%
11,623
+2,018
+21% +$20.1K
BLTE
393
Belite Bio
BLTE
$6.7B
$135K 0.04%
1,831
+318
+21% +$20.9K
PTGX icon
394
Protagonist Therapeutics
PTGX
$9.71B
$134K 0.04%
2,020
+350
+21% +$19.9K
PRAX icon
395
Praxis Precision Medicines
PRAX
$10.2B
$134K 0.04%
2,527
+439
+21% +$21.3K
KROS icon
396
Keros Therapeutics
KROS
$212M
$132K 0.04%
8,342
+1,448
+21% +$21.4K
RVMD icon
397
Revolution Medicines
RVMD
$44.4B
$129K 0.04%
2,768
+481
+21% +$18.8K
ARVN icon
398
Arvinas
ARVN
$588M
$128K 0.04%
15,031
+2,609
+21% +$19.8K
ANNX icon
399
Annexon
ANNX
$883M
$128K 0.04%
41,987
+7,289
+21% +$18.1K
SRRK icon
400
Scholar Rock
SRRK
$6.32B
$127K 0.04%
3,415
+593
+21% +$20.7K
14 15
16
17 18

Similar funds

WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
HS
HighVista Strategies Boston, Massachusetts $362M AUM 230.96% 1-Year Est. Return
SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return
RGC
Roberts, Glore & Co Deerfield, Illinois $364M AUM 19.54% 1-Year Est. Return

Virtus Investment Advisers's Q3 2025 Portfolio in Review

As of Q3 2025, Virtus Investment Advisers held 478 positions worth $349M, up 18% from $296M the previous quarter. Its ten largest holdings account for 7.1% of the portfolio.

Virtus Investment Advisers deployed $36.4M of net new capital in Q3 2025, opening 39 new positions and adding to 273 existing holdings. Its largest new stake was Oxford Lane Capital: 129,209 shares worth $2.19M.

By sector, the portfolio is most concentrated in Financials at 33% of assets, up from 33% a quarter earlier, followed by Healthcare and Technology.

On the sell side, the largest reduction was Incyte, an estimated $1.85M trimmed.

  • Virtus Investment Advisers's largest Q3 2025 buy was Oxford Lane Capital: 129,209 shares worth $2.19M.
  • Virtus Investment Advisers added most to Prospect Capital in Q3 2025, an estimated $697K increase.
  • Virtus Investment Advisers's biggest Q3 2025 reduction was Incyte, cutting an estimated $1.85M.
  • Virtus Investment Advisers fully exited KKR & Co in Q3 2025, selling an estimated $1.62M.
  • Virtus Investment Advisers's ten largest holdings make up 7.1% of its $349M portfolio in Q3 2025.
  • Virtus Investment Advisers opened 39 new positions and closed 38 in Q3 2025.
  • Virtus Investment Advisers's portfolio value rose 18% quarter-over-quarter to $349M.

Based on Virtus Investment Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.